Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms
Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms
复制标题
DOI：
10.1016/s0167-5877(96)01119-1
复制
发表时间：
1997-07-01
影响因子：
2.6
通讯作者：
Aarestrup, FM
中科院分区：
文献类型：
--
作者：
Bager, F;Madsen, M;Aarestrup, FM
我们确定了使用糖肽类抗生素阿伏帕星作为生长促进剂与家禽和养猪场中对万古霉素具有高水平耐药性（MIC大于或等于64 μ g ml（-1））的屎肠球菌（VREF）的发生之间的关联。这些调查是作为回顾性队列研究进行的，比较了1994年9月至1995年4月期间暴露或未暴露于阿伏帕菌素的农场。在家禽中，使用阿伏帕星与VREF发生之间的关联被使用广谱抗生素混淆，调整后的相对风险为2.9（1.4-5.9）。在猪中，这种关联具有类似的幅度，未校正的相对风险为3.3（0.9-12.3）。这两项研究的类似结果提供了支持使用阿伏帕辛与农场发生VREF之间存在因果关系的证据，并表明食用动物构成了人类VREF感染的潜在宿主。(C)1997年Elsevier Science B.V.
We determined the association between the use of the glycopeptide antibiotic avoparcin as a growth promoter and the occurrence of Enterococcus faecium (VREF) with high-level resistance to vancomycin (MIC greater than or equal to 64 mu g ml(-1)) on poultry and pig farms. The investigations were conducted as retrospective cohort studies, where groups of farms exposed or not exposed to avoparcin between September 1994 and April 1995 were compared. In poultry, the association between the use of avoparcin and the occurrence of VREF was confounded by the use of broad-spectrum antibiotics, and the adjusted relative risk was 2.9 (1.4-5.9). In pigs, the association had a similar magnitude with a non-adjusted relative risk of 3.3 (0.9-12.3). The similar findings in the two studies provide evidence in favour of a causal association between the use of avoparcin and the occurrence of VREF on farms, and suggest that food animals constitute a potential reservoir of infection for VREF in humans. (C) 1997 Elsevier Science B.V.